{"id":"W1919283206","doi":"10.1016/j.jaad.2015.03.049","title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":669,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Ortho-McNeil Pharmaceutical; Janssen Pharmaceuticals; Johnson and Johnson; Janssen Biotech; 3M; Merck Sharp and Dohme; Biogen Idec; Genentech; LEO Pharma; Abbott Laboratories; National Institute for Health and Care Research; Sandoz; Novartis; Celgene; Merck; GlaxoSmithKline; Astellas Pharma US; Galderma; Eli Lilly and Company; Pfizer; Amgen; AbbVie; Society of Daughters of the United States Army; Allergan; Merz Therapeutics","keywords":"Apremilast; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Dermatology; Phosphodiesterase inhibitor; Phosphodiesterase; Internal medicine; Pharmacology; Clinical trial; Psoriatic arthritis; Enzyme","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002691841,0.0003883426,0.003836533,0.0004079342,0.00007831598,0.0000093772,0.0005254612,0.0002691033,0.000002998946],"category_scores_gemma":[0.003024415,0.0002076934,0.0003410974,0.0004948365,0.0007896697,0.0001873117,0.0001383505,0.0005931265,6.342948e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008333378,"about_ca_system_score_gemma":0.0003851081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001390558,"about_ca_topic_score_gemma":0.00003208331,"domain_scores_codex":[0.9906915,0.00559742,0.002724572,0.0003188336,0.0002711294,0.0003965161],"domain_scores_gemma":[0.9910508,0.004172739,0.004177646,0.0002775943,0.0002276471,0.00009352442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837151,0.001838279,0.001443861,0.00002981293,0.001095188,0.000007332624,0.003419059,0.0003296461,0.002561916,0.00001440716,0.0001700368,0.005375386],"study_design_scores_gemma":[0.9755228,0.009210651,0.001371943,0.0003532903,0.00103743,0.0001187589,0.0004705492,0.00005912252,0.01157455,0.00006340456,0.0000254659,0.0001919993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931135,0.0008277688,0.00001756255,0.0007702807,0.0007877958,0.004407356,0.00004897023,0.000005924544,0.00002083804],"genre_scores_gemma":[0.9992127,0.0001445401,0.0002650299,0.0001462841,0.0000717505,0.0001124174,0.000007653412,0.0000219673,0.00001763999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009012634,"threshold_uncertainty_score":0.8469492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01953649670246773,"score_gpt":0.3023714075668437,"score_spread":0.282834910864376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}